Shares of STAAR Surgical (NASDAQ:STAA - Get Free Report) have earned a consensus recommendation of "Hold" from the eleven brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $24.63.
Several equities analysts have weighed in on the company. Piper Sandler lowered their target price on STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 12th. StockNews.com lowered STAAR Surgical from a "hold" rating to a "sell" rating in a report on Thursday, February 13th. Wells Fargo & Company started coverage on STAAR Surgical in a report on Monday, April 21st. They set an "equal weight" rating and a $17.00 price target for the company. Jefferies Financial Group cut STAAR Surgical from a "buy" rating to a "hold" rating in a research report on Wednesday, February 12th. Finally, Mizuho cut STAAR Surgical from an "outperform" rating to a "neutral" rating and lowered their price objective for the company from $45.00 to $17.00 in a research report on Wednesday, February 12th.
Read Our Latest Stock Analysis on STAAR Surgical
STAAR Surgical Stock Performance
STAA traded up $0.39 during trading on Friday, reaching $17.82. The company had a trading volume of 178,887 shares, compared to its average volume of 811,251. STAAR Surgical has a 12-month low of $13.50 and a 12-month high of $49.86. The firm's 50-day simple moving average is $17.61 and its 200 day simple moving average is $21.74. The company has a market cap of $882.65 million, a price-to-earnings ratio of -43.05 and a beta of 0.65.
Insider Buying and Selling at STAAR Surgical
In related news, major shareholder Broadwood Partners, L.P. purchased 259,316 shares of STAAR Surgical stock in a transaction on Thursday, February 27th. The shares were purchased at an average price of $17.05 per share, for a total transaction of $4,421,337.80. Following the transaction, the insider now owns 11,548,753 shares of the company's stock, valued at approximately $196,906,238.65. This represents a 2.30% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders purchased 1,482,965 shares of company stock valued at $24,523,688 in the last three months. Corporate insiders own 1.00% of the company's stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC grew its holdings in shares of STAAR Surgical by 349.4% in the third quarter. Barclays PLC now owns 91,707 shares of the medical instruments supplier's stock valued at $3,406,000 after acquiring an additional 71,301 shares in the last quarter. Franklin Resources Inc. raised its position in STAAR Surgical by 80.1% during the third quarter. Franklin Resources Inc. now owns 31,844 shares of the medical instruments supplier's stock valued at $1,183,000 after purchasing an additional 14,162 shares in the last quarter. JPMorgan Chase & Co. raised its position in STAAR Surgical by 411.7% during the third quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier's stock valued at $7,978,000 after purchasing an additional 172,779 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of STAAR Surgical by 21.2% during the fourth quarter. Exchange Traded Concepts LLC now owns 36,374 shares of the medical instruments supplier's stock valued at $884,000 after buying an additional 6,354 shares during the last quarter. Finally, KBC Group NV grew its stake in shares of STAAR Surgical by 5,700.9% in the fourth quarter. KBC Group NV now owns 96,585 shares of the medical instruments supplier's stock worth $2,346,000 after purchasing an additional 94,920 shares during the last quarter. 96.70% of the stock is owned by institutional investors and hedge funds.
STAAR Surgical Company Profile
(
Get Free ReportSTAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Recommended Stories
Before you consider STAAR Surgical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STAAR Surgical wasn't on the list.
While STAAR Surgical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
